Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations.
Administration, Oral
Aged
Aged, 80 and over
Anticoagulants
/ administration & dosage
Antifibrinolytic Agents
/ administration & dosage
Antithrombin III
/ analysis
Aortic Aneurysm
/ complications
Biomarkers
/ blood
Blood Vessels
/ abnormalities
Disseminated Intravascular Coagulation
/ diagnosis
Female
Fibrinolysin
/ analysis
Heparin, Low-Molecular-Weight
/ administration & dosage
Humans
Male
Partial Thromboplastin Time
Peptide Hydrolases
/ analysis
Protease Inhibitors
/ administration & dosage
Prothrombin Time
Thrombomodulin
/ administration & dosage
Tranexamic Acid
/ administration & dosage
alpha-2-Antiplasmin
/ analysis
Aortic aneurysm
Direct oral anticoagulant (DOAC)
Disseminated intravascular coagulation
Fibrinolytic activation
Vascular malformations
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
29
09
2020
accepted:
22
10
2020
revised:
04
10
2020
pubmed:
12
11
2020
medline:
12
2
2021
entrez:
11
11
2020
Statut:
ppublish
Résumé
Aortic aneurysms and vascular malformations are sometimes associated with disseminated intravascular coagulation (DIC). A typical blood coagulation test shows decrease in platelet count and fibrinogen, and increases in fibrin/fibrinogen degradation products (FDP) and D-dimer. The coagulation activation marker thrombin-antithrombin complex (TAT) and the fibrinolysis activation marker plasmin-α
Identifiants
pubmed: 33175341
doi: 10.1007/s12185-020-03028-z
pii: 10.1007/s12185-020-03028-z
doi:
Substances chimiques
Anticoagulants
0
Antifibrinolytic Agents
0
Biomarkers
0
Heparin, Low-Molecular-Weight
0
Protease Inhibitors
0
Thrombomodulin
0
alpha-2-Antiplasmin
0
antithrombin III-protease complex
0
plasmin-plasmin inhibitor complex
0
Tranexamic Acid
6T84R30KC1
Antithrombin III
9000-94-6
Peptide Hydrolases
EC 3.4.-
Fibrinolysin
EC 3.4.21.7
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
15-23Références
Nordon IM, Hinchliffe RJ, Holt PJ, Loftus IM, Thompson MM. Review of current theories for abdominal aortic aneurysm pathogenesis. Vascular. 2009;17:253–63.
pubmed: 19769804
Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care. 2014;2:20.
pubmed: 25520834
pmcid: 4267600
Yamada S, Okumura H, Morishita E, Asakura H. Complete hemostasis achieved by factor XIII concentrate administration in a patient with bleeding after teeth extraction as a complication of aplastic anemia and chronic disseminated intravascular coagulation. Blood Coagul Fibrinolyisis. 2020;31:274–8.
Fine NL, Applebaum J, Elguezabal A, Castleman L. Multiple coagulation defects in association with dissecting aneurysm. Arch Intern Med. 1967;119:522–6.
pubmed: 6024665
Levi M, Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586–92.
pubmed: 10451465
Fisher DF Jr, Yawn DH, Crawford ED. Preoperative disseminated intravascular coagulation associated with aortic aneurysms. A prospective study of 76 cases. Arch Surg. 1983;118:1252–5.
pubmed: 6639333
Tencare JW, Timmers H, Becker AE. Coagulopathy in ruptured or dissecting aortic aneurysm. Am J Med. 1975;59:171–6.
Mukaiyama H, Shinoyama S, Ikezawa T, Kamiya T, Hamaguchi M, Saito H. Abdominal aortic aneurysm complicated with chronic disseminated intravascular coagulopathy: a case of surgical treatment. J Vasc Surg. 1987;6:600–4.
pubmed: 3121870
Baumgartner HR, Stemerman MB, Spaet TH. Adhesion of blood platelets to subendothelial surface: distinct from adhesion to collagen. Experienta. 1971;27:283.
Prentice CRM, McNicol GP, Douglas AS. Effects on blood coagulation of normal and atheromatous aortic tissue. J Clin Path. 1966;19:154–8.
pubmed: 5909696
Hayashi T, Morishita E, Ohtake H, Oda Y, Asakura H, Nakao S. Expression of annexin II in experimental abdominal aortic aneurysms. Int J Hematol. 2009;90:336–42.
pubmed: 19756921
Hayashi T, Morishita E, Ohtake H, Oda Y, Ohta K, Arahata M, et al. Expression on annexin II in human artherosclerotic abdominal aortic aneurysms. Thromb Res. 2008;123:274–80.
pubmed: 18502476
Hajjar KA, Menell JS. Annexin II: a novel mediator of cell surface plasmin generation. Ann NY Acad Sci. 1997;811:337–49.
pubmed: 9186609
Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem. 1994;269:21191–7.
pubmed: 8063740
Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem. 1994;269:21198–203.
pubmed: 8063741
Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J med. 1999;340:994–1004.
pubmed: 10099141
Madoiwa S, Someya T, Hironaka M, Kobayashi H, Ohmori T, Mimuro J, et al. Annexin 2 and hemorrhagic disorder in vascular intimal carcinomatosis. Thromb Res. 2007;119:229–40.
pubmed: 16524621
Ohno Y, Izumi M, Kawamura T, Nishimura T, Mukai K, Tachibana M. Annexin II represents metastatic potential in clear-cell renal cell carcinoma. Br J Cancer. 2009;101:287–94.
pubmed: 19513064
pmcid: 2720210
Shiozawa Y, Havens AM, Jung Y, Ziegler AM, Pedersen EA, Wang J, et al. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem. 2008;105:370–80.
pubmed: 18636554
pmcid: 3614912
Wada H, Thachil J, Di Nisio M, Mathew P, Kuwosawa S, Gando S, et al. Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines. J Thromb Haemos. 2013;11:761–7.
Aboulafia DM, Aboulafia ED. Aortic aneurysm-induced disseminated intravascular coagulation. Ann Vasc Surg. 1996;10:396–405.
pubmed: 8879398
Tanaka K, Ito K, Ohgi S, Tsujimoto M, Okada M, Hara H, et al. Abdominal aortic aneurysm complicated by disseminated intravascular coagulation(DIC). J Jpn Surg Assoc. 1987;48:829–32.
Kotani S. A case of disseminated intravascular coagulation after thoracic endovascular aortic repair. Ann Vasc Dis. 2015;8:334–6.
pubmed: 26730263
pmcid: 4691512
Takahashi K, Ichikawa Y, Arimori S. Disseminated intravascular coagulation related to artheriosclerosis and aneurysm of aorta: successful management with self-subcutaneous injection of heparin sodium. Rinsho Ketsueki. 1989;30:1820–5.
pubmed: 2593249
Yamamoto K, Ito H, Hiraiwa T, Tanaka K. Effects of nafamostat mesilate on coagulopathy with chronic aortic dissection. Ann Thorac Surg. 2009;88:1331–3.
pubmed: 19766834
Minakata D, Fujiwara S, Ikeda T, Kawaguchi S, Toda Y, Ito S, et al. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol. 2019;109:141–6.
pubmed: 30536180
Yoneda K, Amano I, Tanaka H, Yagi H, Tsukaguchi N, Morii T, et al. Effective use of camostat mesylate for chronic disseminated intravascular coagulation complicated by thoracoabdominal aortic aneurysm. Rinsho Ketsueki. 2001;42:30–4.
pubmed: 11235131
Hoshina K, Shigematsu K, Hosaka A, Okamoto H, Miyata T, Watanabe T. The effect of recombinant human soluble thrombomodulin on disseminated intravascular coagulation in abdominal aortic aneurysm. Blood Coagul Fibrinolysis. 2014;25:389–91.
pubmed: 24378974
Ikezoe T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. Int J Hematol. 2020. https://doi.org/10.1007/s12185-020-02992-w .
doi: 10.1007/s12185-020-02992-w
pubmed: 32902759
Aota T, Wada H, Yamashita Y, Matsumoto T, Ohishi K, Suzuki K, et al. The efficacy of the administration of recombinant human soluble thrombomodulin in patients with DIC. Int J Hematol. 2016;103:173–9.
pubmed: 26590919
Yokoyama H, Takahashi N, Katsuoka Y, Inomata M, Ito T, Meguro K, et al. Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum. Int J Hematol. 2017;105:606–13.
pubmed: 28176226
Danhof A, de Boer A, Magnani HN, Stiekema JC. Pharmacokinetic considerations on Orgaran (Org10172) therapy. Hemostasis. 1992;22:73–84.
Togami K, Nagai Y, Arima H, Shimoji S, Kimura T, Inoue D, et al. Successful treatment of chronic disseminated intravascular coagulation syndrome with continuous subcutaneous infusion of heparin using a mobile infusion pump: report of 2 cases. Rinsho Ketsueki. 2009;50:1700–5.
pubmed: 20068277
Oba J, Shiiya N, Matsui Y, Goda T, Sakuma M, Yasuda K. Preoperative disseminated intravascular coagulation (DIC) associated with aortic aneurysm—dose it need to be corrected before surgery? Surg Today. 1995;25:1011–4.
pubmed: 8645932
Cummins D, Segal H, Hunt BJ, Awad R, Maddox A. Chronic disseminated intravascular coagulation after surgery for abdominal aortic aneurysm: clinical and haemostatic response to dalteparin. Br J Haematol. 2001;113:658–60.
pubmed: 11380454
Ontachi Y, Asakura H, Arahata M, Kadohira Y, Maekawa M, Hayashi T, et al. Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm. Circ J. 2005;69:1150–3.
pubmed: 16127203
Fujii S, Hitomi Y. New synthetic inhibitors of C
pubmed: 6271224
Tsukagoshi S. Pharmacokinetics studies of nafamostat mesylate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation. Gan To Kagaku Ryoho. 2000;27:767–74.
pubmed: 10832450
Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesylate. Gen Pharmacol. 1995;26:1627–32.
pubmed: 8745149
Asakura H, Ogawa H. Potential of heparin and nafamostat combination therapy for COVID-19. J Thromb Haemost. 2020;18:1521–2.
pubmed: 32302456
Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.
pubmed: 17059423
Kazuno K, Murata S, Sato H, Urata M. Efficacy of recombinant human soluble thrombomodulin in an outpatient with chronic disseminated intravascular coagulation complicating thoracic aortic aneurysm after TEVAR. J Jpn Coll Angiol. 2016;56:35–8.
Ito T, Watanabe T, Uchiyama H, Yasuda N, Kawaharada N. Preoperative recombinant thrombomodulin treatment for disseminated intravascular coagulation in patients with aortic pathology. J Jpn Surg Assoc. 2017;78:1506–10.
Hayakawa K, Tamura S, Gima H, Hayakawa T, Kurihara T, Ooura M, et al. Successful treatment of chronic disseminated intravascular coagulation using recombinant human soluble thrombomodulin in a dialysis patient with dissecting aortic aneurysm. Rinsho Ketsueki. 2014;55:2300–5.
pubmed: 25501411
Hayashi T, Nakagawa N, Kadohira Y, Morishita E, Asakura H. Rivaroxaban in a patient with disseminated intravascular coagulation associated with an aortic aneurysm: a case report. Ann Intern Med. 2014;161:158–9.
pubmed: 25023258
Kadohira Y, Yamada S, Matsuura E, Hayashi T, Morishita E, Nakao S, et al. Aortic aneurysm-associated disseminated intravascular coagulation that responded well to a switch from warfarin to rivaroxaban. Intern Med. 2017;56:2913–7.
pubmed: 28943552
pmcid: 5709638
Kawano H, Hata T, Uda A, Maemura K. Use of rivaroxaban for the effective management of disseminated intravascular coagulation associated with abdominal aortic aneurysm. Intern Med. 2015;54:2625–8.
pubmed: 26466700
Ito T, Mikami T, Numaguchi R, Watanabe T, Nakazawa J, Kawaharada N. A case of disseminated intravascular coagulation caused by dissecting aortic aneurysm in which coagulation factor XIII was effective for hemostasis. Jpn J Vasc Surg. 2018;27:247–50.
Munter G, Hershko C. Increased warfarin sensitivity as an early manifestation of occult prostate cancer with chronic disseminated intravascular coagulation. Acta Haematol. 2001;105:97–9.
pubmed: 11408712
Otsui K, Yamamoto M, Aoki H, Ozawa T, Domoto K, Suzuki A, et al. A super-elderly case of abdominal aortic aneurysm associated with chronic disseminated intravascular coagulation. J Cardiol Cases. 2014;26:48–51.
Werbin A, Fong A, Shahin G, Henderson A, Surry L. Tranexamic acid use in a patient with a life threatening bleed exacerbated by coagulopathy due to an aortic aneurysm with an endoleak: a case report. Cureus. 2019;11:e5486.
pubmed: 31489276
pmcid: 6713243
Naeye RL. Thrombotic state after a hemorrhagic diathesis, a possible complication of therapy with epsilon-aminocaproic acid. Blood. 1962;19:694–701.
pubmed: 14477845
Charytan C, Purtilo D. Glomerular capillary thrombosis and acute renal failure after epsilon-amino caproic acid therapy. N Engl J Med. 1969;280:1102–4.
pubmed: 5778426
Ogawa H, Asakura H. Consideration of tranexamic acid administration to COVID-19 patients. Physiol Rev. 2020;100:1595–6.
pubmed: 32639181
pmcid: 7365834
Taniguchi M, Ueda Y, Toyoda K, Maeda M. An operated case of retroperitoneal cavernous hemangioma complicated by Kasabach-Merritt syndrome. J Jpn Surg Assoc. 1995;56:1459–63.
Beier UH, Schmidt ML, Hast H, Kecskes S, Valentino LA. Control of disseminated intravascular coagulation in Klippel-Trenaunay-Weber syndrome using enoxaparin and recombinant activated factor VIIa: a case report. J Med Case Rep. 2010;4:92.
pubmed: 20302608
pmcid: 2848681
Hashimoto Y, Eto K, Uchino M, Araki S. Blue-rubber-bleb-nevus syndrome presented vascular dementia and chronic DIC—a case report. Rinsho Shinkeigaku. 1989;29:202–8.
pubmed: 2752649
Wada O, Unno N, Matsuoka R, Taketani Y. A case report: pregnancy complicated by blue rubber-bleb nevus syndrome. J Obstet Gynecol Res. 1999;25:261–3.
Mimura H, Akita S, Fujino A, Jinnin M, Ozaki M, Osuga K, et al. Japanese clinical practice guidelines for vascular anomalies 2017. Jpn J Radiol. 2020;38:287–342.
pubmed: 32207066
pmcid: 7150662
Kasabach HH, Merritt KK. Caplillary hemangioma with extensive purpura: report of a case. Am J Dis Child. 1940;59:1063–70.
Heit JJ, Do HM, Prestigiacomo CJ, Delgado-Almandoz JA, English J, Gandhi CD, et al. Guidelines and parameters: percutaneous sclerotherapy for the treatment of head and neck venous and lymphatic malformations. J Neurointerv Surg. 2017;9:611–7.
pubmed: 26801946
Steiner F, FitzJohn T, Tan ST. Surgical treatment for venous malformation. J Plast Reconstr Aesthet Surg. 2013;66:1741–9.
pubmed: 24012651
Ma LW, Levi B, Oppenheimer AJ, Kasten SJ. Intralesional laser therapy for vascular malformations. Ann Plast Surg. 2014;73:547–51.
pubmed: 24625513
Langbroek GB, Horbach SE, van der Vleuten CJ, Ubbink DT, van der Horst CM. Compression therapy for congenital low-flow vascular malformations of the extremities: a systematic review. Phlebology. 2018;33:5–13.
pubmed: 28429627
Dompmartin A, Acher A, Thibon P, Tourbach S, Hermans C, Deneys V, et al. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol. 2008;144:873–7.
pubmed: 18645138
pmcid: 5572565
Yasumoto A, Ishiura R, Narushima M, Yatomi Y. Successful treatment with dabigatran for consumptive coagulopathy associated with extensive vascular malformations. Blood Coagul Fibrinolysis. 2017;28:670–4.
pubmed: 28938309
pmcid: 5708713
Vandenbriele C, Vanassche T, Peetermans M, Verhamme P, Peerlinck K. Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation. J Thromb Thrombolysis. 2014;38:121–3.
pubmed: 24202701
Mack JM, Richter GT, Crary SE. Effectiveness and safety of treatment with direct oral anticoagulant rivaroxaban in patients with slow-flow vascular malformations: a case series. Lymphat Res Biol. 2018;16:278–81.
pubmed: 29583078